Inhibition of insulin-like growth factor-I mitogenic action by zinc chelation is associated with a decreased mitogen-activated protein kinase activation in RAT-1 fibroblasts  by Lefebvre, Donatienne et al.
Inhibition of insulin-like growth factor-I mitogenic action by zinc
chelation is associated with a decreased mitogen-activated protein kinase
activation in RAT-1 ¢broblasts
Donatienne Lefebvrea, Charlotte M. Boneyb, Jean-Marie Ketelslegersa, Jean-Paul Thissena;1;*
a Diabetes and Nutrition Unit, Universite¤ Catholique de Louvain, B-1200 Brussels, Belgium
b Department of Pediatrics, Brown University, Providence, RI 02903, USA
Received 4 March 1999
Abstract The mechanisms responsible for the resistance to the
anabolic actions of IGF-I induced by zinc deficiency are not
understood. We showed that zinc chelation by DTPA (diethyl-
enetriaminepenta-acetic acid) inhibits [3H]thymidine incorpora-
tion stimulated by IGF-I in Rat-1 fibroblasts. This inhibition was
specific of zinc chelation since it was prevented by the addition of
zinc to DTPA. The stimulation of MAPK, which is crucial for
the [3H]thymidine incorporation induced by IGF-I in Rat-1 cells,
was partially blunted by DTPA. Therefore, the inhibition of the
mitogenic action of IGF-I in Rat-1 fibroblasts by DTPA is
potentially caused by decreased MAPK activation by IGF-I.
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1. Introduction
Insulin-like growth factor-I (IGF-I) is an important growth
factor which mediates many of the growth-promoting e¡ects
of growth hormone (GH). In animals and in humans, dietary
zinc de¢ciency causes growth retardation associated with re-
duced circulating IGF-I concentrations [1^4]. IGF-I adminis-
tration to zinc-deprived rats fails, however, to restore the
growth despite the normalization of plasma IGF-I levels [5].
These observations suggest that zinc de¢ciency induces a state
of resistance to the growth-promoting actions of IGF-I.
To investigate the mechanisms by which zinc de¢ciency
could inhibit the growth-promoting actions of IGF-I, we
studied the e¡ects of zinc chelation on the mitogenic and
anabolic actions of IGF-I in Rat-1 ¢broblasts. Indeed, IGF-
I is known to stimulate the proliferation and amino acid
transport in these cells [6,7]. Because the mitogen-activated
protein kinase (MAPK) signalling cascade is important for
the mitogenic action of IGF-I [8], we also investigated
whether inhibition of IGF-I mitogenic action by zinc chela-
tion was associated with a decreased activation of the MAPK
isoforms ERK1 and ERK2.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle medium (DMEM), fetal bovine serum
(FBS), antibiotics and glutamine were obtained from Life Technolo-
gies (Merelbeke, Belgium). IGF-I was a gift from Pharmacia-Upjohn
(Uppsala, Sweden). DTPA (diethylenetriaminepenta-acetic acid) and
ZnSO4 were purchased from Sigma Chemical (St Louis, MO, USA).
[3H]thymidine was obtained from Amersham (Buckinghamshire, UK,
speci¢c activity(SA): 25 Ci/mmol) and [methyl-3H]AIB was obtained
from ICN Biomedicals (Asse-Relegem, Belgium, SA: 1-10 Ci/mmol).
2.2. Cell culture
Rat-1 ¢broblasts, kindly provided by Dr P. Courtoy (ICP, Brussels,
Belgium) were cultured in DMEM, as described previously [9].
2.3. [3H]thymidine incorporation assay
Cells were seeded (104 cells/well) in 96 well tissue culture plates
(NUNC, Naperville, IL, USA) in DMEM with 10% FBS. 24 h after
plating, cells were exposed for di¡erent times to IGF-I in serum-free
medium with 0.1% BSA (control group). In order to test the conse-
quences of zinc de¢ciency on the mitogenic action of IGF-I, 40 WM
DTPA (DTPA group) or 40 WM DTPA with 40 WM ZnSO4
(DTPA+ZnSO4 group) were added to the culture medium. 5 h prior
to the cell harvest, [3H]thymidine (1 WCi) was added. Cells were
washed, detached in trypsin-EDTA and harvested onto glass-¢ber
¢lters using a cell harvester Filtermate 196 (Packard, Meriden, CT,
USA). The counts per well of triplicate or sixplicate determinations
were determined using a microplate L-scintillation counter (Packard),
averaged and expressed as the percentage of total counts in untreated
cells
2.4. [Methyl-3H]AIB uptake
Cells were seeded (6U104 cells/well) in 24 well tissue culture plates
(NUNC) in DMEM with 10% FBS for 48 h with a change of the
medium after 24 h. IGF-I stimulation of the [methyl-3H]AIB uptake
was performed as described previously [10]. IGF-I was added for 6 h
to duplicate wells in HBSS (control group) or in the presence of 40
WM DTPA, or 40 WM DTPA and 40 WM ZnSO4. The counts per well
of duplicate determinations were averaged and expressed as the per-
centage of counts in untreated cells.
2.5. MAPK assay
Cells were seeded (3U105 cells/well) in six well plates in DMEM
with 10% FBS for 48 h. Cells were then washed and incubated in
triplicate in serum-free medium or in the presence of 40 WM DTPA
or 40WM DTPA plus 40WM ZnSO4 for 24 h. IGF-I was then added
for 2, 5, 10 or 15 min. The IGF-I stimulation was stopped by chilling
plates on ice and removing the medium. Cells were washed, scraped in
MAPK lysis bu¡er [11] and the lysates from triplicate wells were
pooled. Cell lysates were resolved by SDS-PAGE on 10% gels and
then transferred to Hybond C nitrocellulose (Amersham Life Science,
Arlington Heights, IL, USA). Western blotting of catalytically active
MAPK was performed using an anti-phospho-MAPK antibody at
1 Wg/ml that recognizes dual-phosphorylated ERK1 and ERK2
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(New England Biolabs, Beverly, MA, USA). The blots were stripped
and probed with anti-rat MAPK R2 (ERK1-CT) antibody (Upstate
Biotechnology, Lake Placid, NY, USA) at 1 Wg/ml to determine the
total ERK1 and ERK2 contents. Speci¢c binding was visualized using
enhanced chemiluminescence (Amersham Life Science, Arlington
Heights, IL, USA) followed by scanning densitometry. Data are ex-
pressed as the ratio of phosphorylated MAPK/total MAPK.
2.6. Statistical analysis
Data were analyzed according to two-way analysis of variance.
Multiple comparisons were performed using the pairwise Bonferroni
multiple comparison test. Data from Fig. 1 were transformed to their
logarithm before the statistical analyses. On graphs, data are ex-
pressed as the mean þ S.E.M. Di¡erences were considered signi¢cant
when P6 0.05.
3. Results
3.1. The e¡ect of zinc chelation on the mitogenic action of
IGF-I
We ¢rst examined whether zinc chelation could inhibit the
IGF-I-stimulated DNA synthesis in Rat-1 ¢broblasts. As
shown in Fig. 1, IGF-I stimulated dose-dependently the
[3H]thymidine incorporation in these cells. The maximal stim-
ulation (3-fold) was observed at 10 nM IGF-I while the half-
maximal stimulation occurred at 0.4 nM (3 ng/ml). To mimic
a state of zinc de¢ciency, we incubated the cells in the pres-
ence of the speci¢c zinc chelator, DTPA. DTPA decreased the
basal thymidine incorporation by 66 þ 8% (DTPA w/o IGF-I
versus control w/o IGF-I, P6 0.01, n = 3, Fig. 1). DTPA also
markedly inhibited the maximal IGF-I stimulation of
[3H]thymidine incorporation (by 75% at 10 nM IGF-I,
P6 0.001). The inhibition of IGF-I-stimulated [3H]thymidine
incorporation by 40 WM DTPA was almost completely pre-
vented by the addition of 40 WM ZnSO4 (20 nM IGF-I, 3-fold
stimulation versus 20 nM IGF-I+DTPA+ZnSO4, 2.8-fold
stimulation: not signi¢cant (N.S.) (Fig. 1).
The mitogenic action of IGF-I in Rat-1 cells was also con-
¢rmed by the increase of the total DNA content (+22% at 5^
10 nM IGF-I, P6 0.05, n = 3) (data not shown). Similarly to
the [3H]thymidine incorporation, the increase in the DNA
content induced by IGF-I was also inhibited by DTPA and
restored to normal by the addition of ZnSO4.
The kinetic analysis of the inhibition of the IGF-I mitogenic
action by DTPA (data not shown) indicated that DTPA in-
hibited time-dependently the IGF-I-induced thymidine incor-
poration (by 50% after 12 h, by 90% after 18 h and by 97%
after 24 h, P6 0.001, n = 2). Together, these data demon-
strated that zinc chelation by DTPA blocked the IGF-I-stimu-
lated DNA synthesis.
3.2. The e¡ect of zinc chelation on IGF-I-stimulated
[methyl-3H]AIB uptake
We questioned whether DTPA might inhibit other biolog-
ical actions of IGF-I such as the amino acid uptake in Rat-1
¢broblasts. While DTPA, alone or together with ZnSO4, de-
creased the basal [methyl-3H]AIB uptake by respectively
24 þ 4% and 21 þ 4% (N.S., n = 3), the stimulation by IGF-I
of the [methyl-3H]AIB uptake was not impaired by DTPA or
DTPA+ZnSO4 (10 nM IGF-I stimulation by 1.9-fold, 10 nM
IGF-I+DTPA by 1.8-fold, 10 nM IGF-I+DTPA+ZnSO4 by
1.6-fold: N.S., n = 2) (Fig. 2). These data showed that zinc
chelation by DTPA did not inhibit the amino acid uptake
induced by IGF-I in Rat-1 ¢broblasts.
Fig. 1. The e¡ect of zinc chelation by DTPA on the IGF-I-stimu-
lated [3H]thymidine incorporation in Rat-1 ¢broblasts. Results are
expressed as percentage of the values observed in untreated cells
(control w/o IGF-I: 8367 þ 1298 cpm/well). Data are the mean þ
S.E.M. of three separate experiments. *, P6 0.05; **, P6 0.01 and
***, P6 0.001 versus the corresponding DTPA group at each IGF-I
concentration. , P6 0.05 versus the control group at the di¡erent
IGF-I concentrations.
Fig. 2. The e¡ect of zinc chelation by DTPA on the IGF-I-stimu-
lated [methyl-3H]AIB uptake in Rat-1 ¢broblasts. Results are ex-
pressed as percentage of the values observed in untreated cells (con-
trol w/o IGF-I: 3286 þ 495 cpm/well). Data are the mean þ S.E.M.
of three separate experiments. **, P6 0.01 versus the control group
w/o IGF-I and  versus the control group at the di¡erent IGF-I
concentrations.
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3.3. The e¡ect of zinc chelation on the IGF-I-stimulated
MAPK activity
Given that the activation of the MAPK isoforms ERK1
and ERK2 is a common pathway used by IGF-I and other
growth factors to stimulate mitogenesis [12], we examined the
e¡ect of zinc chelation on the MAPK activation by IGF-I. We
¢rst determined that this pathway is involved in the stimula-
tion of [3H]thymidine incorporation by IGF-I in Rat-1 ¢bro-
blasts. The addition of PD98059, a speci¢c inhibitor of the
MAPK kinase (MEK) activity [13,14], completely inhibited
indeed the stimulation of the [3H]thymidine incorporation
by IGF-I (by 88% at 10 WM PD98059 and by 96% at 50
WM, P6 0.001) (Fig. 3A). In the absence of IGF-I,
PD98059 also inhibited the basal [3H]thymidine incorpora-
tion. By measuring dual-phosphorylated MAPK, we showed
that IGF-I induced the MAPK activation in a time-dependent
manner (maximum of 4.5-fold at 2 min, P6 0.001, n = 2) and
we con¢rmed that the MAPK activation by IGF-I was pre-
vented by pretreatment with the inhibitor PD98059 (by 57%
at 10 WM PD98059, P6 0.05 and by 79% at 50 WM, P6 0.01)
(Fig. 3B and C). In the absence of IGF-I, PD98059 also in-
hibited the basal MAPK phosphorylation. These results dem-
onstrate that p42/p44 MAPKs are involved in the stimulation
of thymidine incorporation by IGF-I in Rat-1 ¢broblasts. We
then examined the e¡ect of zinc chelation on the MAPK
activation by IGF-I. The IGF-I stimulation of MAPK was
signi¢cantly blunted by DTPA, by 31% at 2 min and by 42%
at 5 min (P6 0.01 versus IGF-I group, n = 2) (Fig. 4). The
addition of ZnSO4 concomitantly to DTPA almost completely
Fig. 3. The e¡ect of PD98059 on the stimulation by IGF-I of
the[3H]thymidine incorporation and MAPK phosphorylation in Rat-
1 ¢broblasts. (A) [3H]thymidine incorporation. Results are expressed
as the percentage of the values observed in untreated cells (w/o
IGF-I and w/o PD98059: 24646 þ 526 cpm/well). Data are the
mean þ S.E.M. of sixplicates of one experiment. ***, P6 0.001 ver-
sus w/o IGF-I and w/o PD98059, , P6 0.001 versus IGF-I w/o
PD98059. (B) Western blot of active MAPK and total MAPK. (C)
A densitometric analysis of the Western blot of active MAPK and
total MAPK was used to determine the ratio of phosphorylated
MAPK to total MAPK. Results are expressed as the percentage of
the values observed in untreated cells (w/o IGF-I and w/o
PD98059). Data are the mean þ S.E.M. of triplicates of one experi-
ment. *, P6 0.05 versus w/o IGF-I and w/o PD98059; , P6 0.05
and , P6 0.01 versus IGF-I w/o PD98059.
Fig. 4. Time course of the e¡ect of zinc chelation by DTPA on the
stimulation of the MAPK phophorylation by IGF-I in Rat-1 ¢bro-
blasts. (A) Representative Western blot of active MAPK and total
MAPK. (B) Densitometric analysis of the Western blot was used to
determine the ratio of phosphorylated MAPK to total MAPK. Re-
sults are expressed as the percentage of the values observed in un-
treated cells (w/o IGF-I at time 0). Data are the mean þ S.E.M. of
two separate experiments. ***, P6 0.001 versus control 0P ; ,
P6 0.05 between the groups IGF-I and IGF-I+DTPA+ZnSO4, ,
P6 0.01 between the groups IGF-I and IGF-I+DTPA.
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restored the levels of phosphorylated MAPK (88% of the
control values at 2 and 5 min, IGF-I group versus IGF-
I+DTPA+ZnSO4 group, N.S., n = 2) (Fig. 4). In the absence
of IGF-I (time 0), DTPA alone did not modify the basal
phosphorylation of MAPK (Fig. 4).
4. Discussion
We showed that zinc chelation by DTPA inhibits the mito-
genic action of IGF-I in Rat-1 ¢broblasts. This inhibition
could be explained by a decrease in the MAPK activation, a
crucial step in the transduction of the mitogenic signal initi-
ated by IGF-I in these cells.
Our study showed that the zinc availability is critical for
DNA synthesis both in basal conditions and in response to
IGF-I. Furthermore, this inhibition of the DNA synthesis, as
assessed by [3H]thymidine incorporation, was con¢rmed by a
decreased cellular DNA content. Therefore, the inhibition of
the DNA synthesis by DTPA suggests that zinc is mandatory
for the cell entry into the S phase of the cell cycle [15^19]. This
conclusion is supported by data of Chesters et al. showing
that zinc is required during the G1 to S phase transition [20].
The inhibition of the DNA synthesis by DTPA was specif-
ically caused by zinc depletion because it was almost com-
pletely prevented by the addition of zinc to DTPA. Further-
more, the addition of Fe3, Co2, Ni2, Mn2, Mg2, Cd2
and Ca2 to DTPA did not restore the stimulation of thymi-
dine incorporation by IGF-I or serum [16,21]. This suggests
that it is the chelation of zinc per se and probably not the
chelation of other divalent cations which was responsible for
these e¡ects. Moreover, these observations also suggest that it
is unlikely that the observed e¡ect of DTPA was due to toxic
e¡ects of the compound itself.
Although zinc chelation completely blocked the IGF-I stim-
ulation of thymidine incorporation, it did not impair the stim-
ulation of amino acid uptake, another biological action of
IGF-I. This suggests that the bioavailability of IGF-I is not
altered by zinc chelation and that the mechanism of inhibition
of the IGF-I mitogenic action by zinc chelation is likely a
post-receptor defect. Although DTPA slightly decreased the
basal amino acid uptake, the decrease was not prevented by
zinc addition, suggesting that this e¡ect is not the consequence
of zinc depletion and might be due to the chelation of other
divalent cations important for the transport of amino acids.
To further elucidate the mechanisms by which zinc chela-
tion inhibits the mitogenic action of IGF-I, we investigated
the e¡ect of zinc chelation on post-receptor signal transduc-
tion. It has been recently shown that the DTPA inhibition of
IGF-I stimulation of the DNA synthesis in Swiss 3T3 ¢bro-
blasts is not mediated by a decrease in IGF-I receptor levels
[21^22]. In our study, we determined whether the inhibition by
DTPA of the IGF-I mitogenic action was associated with an
alteration in the MAPK activation, an important signalling
cascade utilized by several growth factors to mediate mito-
genesis [12]. Using PD98059 to inhibit the activation of
MAPK [13,14], we demonstrated that MAPK activation is
crucial for the stimulation of [3H]thymidine incorporation
by IGF-I in Rat-1 ¢broblasts, as in other cells [23]. Our
data demonstrate for the ¢rst time that zinc chelation by
DTPA decreased the MAPK activation by IGF-I and addi-
tion of zinc to DTPA mostly restored the MAPK activation.
Our study therefore sustains the role of zinc in the activation
of MAPK in response to growth factors, as suggested by Kiss
et al. [19]. Taken together, these observations suggest that
alterations in the MAPK activity might be partially responsi-
ble for the inhibition of the IGF-I-stimulated thymidine in-
corporation by DTPA. Indeed, in Swiss 3T3 cells, Dudley et
al. have established a correlation between the inhibition of
thymidine incorporation and the inhibition of stimulation of
MAPK, using increased concentrations of PD98059 [14]. Our
observation that PD98059 inhibits the MAPK activation by
IGF-I to a lesser extent than thymidine incorporation (Fig. 3)
suggests that a partial decrease of the MAPK activation might
be su⁄cient to induce an almost complete inhibition of the
thymidine incorporation stimulated by IGF-I. The fact that
MAPK phosphorylation levels are not completely restored by
the addition of zinc to DTPA might be explained by a non-
speci¢c chelation by DTPA of Mg2, a divalent cation neces-
sary for the activity of kinases. Although the MAPK activa-
tion by IGF-I was decreased by DTPA, the basal levels of
phosphorylated MAPK (i.e. in the absence of IGF-I) were not
decreased by DTPA. This suggests that DTPA does not act
on the MAPK pathway as PD98059 and that the MAPK
inactivation is not responsible for the decreased basal DNA
synthesis caused by DTPA. Other cellular alterations down-
stream of MAPK (i.e. thymidine kinase) [24,25] and induced
by zinc chelation might explain the decline in basal thymidine
incorporation.
In vivo, dietary zinc de¢ciency induces a growth retardation
and an insensitivity to the action of IGF-I [5]. Our observa-
tion that zinc chelation speci¢cally inhibits the mitogenic ac-
tion of IGF-I suggests that the insensitivity to IGF-I induced
by zinc de¢ciency in vivo might be directly due to a reduced
zinc availability.
In conclusion, we showed that the loss of the mitogenic
activity of IGF-I by zinc chelation in Rat-1 ¢broblasts is
associated with a decrease in the activation of MAPK. This
is the ¢rst demonstration that depletion of a trace element
speci¢cally induces a failure in the mitogenic transduction
signal initiated by a growth factor.
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